Esophageal Cancer — Precision Treatment & Specialist Access

The most common first sign is progressive difficulty swallowing (dysphagia) — initially to solid foods, then to liquids. This is often accompanied by unintentional weight loss and sometimes odynophagia (painful swallowing). Because early esophageal cancer is usually asymptomatic, many patients are diagnosed at an advanced stage. Anyone experiencing new progressive dysphagia should seek medical evaluation promptly.

Squamous cell carcinoma (SCC) arises from the flat squamous cells lining most of the esophagus and is predominantly associated with tobacco and alcohol use. It is the most common type globally, particularly in Asia and Africa. Adenocarcinoma arises from glandular cells in the lower esophagus, is strongly linked to GERD and Barrett's esophagus, and is the dominant subtype in Western countries. The two subtypes differ in their risk factors, anatomical location, and molecular characteristics, which influences treatment strategy.

HER2 positivity means the tumor cells overexpress or amplify the HER2 protein (or gene), which promotes cancer cell growth. Approximately 15–20% of esophageal and gastroesophageal junction adenocarcinomas are HER2 positive. This biomarker qualifies patients for trastuzumab (Herceptin) added to first-line chemotherapy, which has been shown to improve outcomes compared to chemotherapy alone. HER2 testing is now standard before starting systemic therapy.

Early-stage esophageal cancer (Stage I–II) treated with surgery or endoscopic resection can result in long-term disease control and is potentially curable. Even some Stage III patients who achieve a pathologic complete response to neoadjuvant chemoradiation followed by surgery have excellent long-term outcomes. Advanced or metastatic esophageal cancer (Stage IV) is currently not curable with standard therapies, but immunotherapy and targeted therapy have meaningfully extended survival for many patients. The goal of treatment in advanced disease is long-term control and quality of life.

The CROSS protocol is a neoadjuvant (pre-surgery) chemoradiation regimen used for locally advanced esophageal cancer. It involves weekly carboplatin and paclitaxel chemotherapy administered concurrently with radiation therapy, followed by surgery approximately 4–6 weeks after completion. Clinical trials have demonstrated that the CROSS protocol significantly improves pathologic complete response rates and overall survival compared to surgery alone, making it a standard of care for resectable Stage II–III esophageal cancer.

Adjuvant nivolumab is a form of immunotherapy given after neoadjuvant chemoradiation and surgery (esophagectomy) in patients who did not achieve a pathologic complete response (meaning cancer cells were still found in the surgical specimen). Based on the CheckMate 577 trial, nivolumab given for up to 12 months after surgery significantly reduces the risk of cancer recurrence. It is now an approved and recommended part of the standard treatment pathway for eligible patients.

Esophagectomy (surgical removal of part or all of the esophagus) is the standard curative treatment for resectable esophageal cancer beyond early T1a disease. However, not all patients are candidates due to tumor location, extent, or overall health status. For unresectable or medically unfit patients, definitive chemoradiation without surgery can achieve local control and, in some cases, long-term remission — particularly for squamous cell carcinoma. Endoscopic resection is appropriate for T1a mucosal disease at experienced centers.

Nutritional support is one of the most important aspects of esophageal cancer care. Depending on the degree of dysphagia and treatment plan, this may include dietitian-guided dietary modification, nasogastric tube feeding, placement of a feeding jejunostomy (surgically placed tube into the small bowel), or in some cases total parenteral nutrition. Speech-language therapists assist with swallowing rehabilitation, particularly after esophagectomy. Palliative endoscopic stent placement can rapidly restore swallowing in patients with advanced or inoperable disease.

Yes. CancerFax helps esophageal cancer patients access specialist surgical and oncology review, obtain a second opinion on resectability and treatment planning, and identify access to HER2-targeted therapy, immunotherapy, and clinical trials. We coordinate with leading esophageal cancer centers — including high-volume programs in China and India that manage large numbers of SCC and adenocarcinoma patients — and can assist with international medical travel, report translation, and therapy access. Send your reports to begin.